 Atsushi Oba
Concepts (247)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatic Neoplasms | 77 | 2026 | 927 | 12.830 |
Why?
| | Pancreatectomy | 40 | 2026 | 285 | 6.480 |
Why?
| | Carcinoma, Pancreatic Ductal | 21 | 2026 | 292 | 4.670 |
Why?
| | Robotic Surgical Procedures | 15 | 2026 | 182 | 4.180 |
Why?
| | Liver Neoplasms | 24 | 2026 | 783 | 3.530 |
Why?
| | Pancreaticoduodenectomy | 25 | 2025 | 135 | 3.270 |
Why?
| | Hepatectomy | 21 | 2026 | 273 | 3.070 |
Why?
| | Laparoscopy | 13 | 2025 | 475 | 2.520 |
Why?
| | Neoadjuvant Therapy | 20 | 2025 | 463 | 2.340 |
Why?
| | Portal Vein | 9 | 2025 | 114 | 1.710 |
Why?
| | Mesenteric Artery, Superior | 10 | 2026 | 28 | 1.700 |
Why?
| | Mesenteric Veins | 5 | 2025 | 23 | 1.640 |
Why?
| | Colorectal Neoplasms | 12 | 2025 | 848 | 1.550 |
Why?
| | Bile Duct Neoplasms | 7 | 2025 | 128 | 1.390 |
Why?
| | Vascular Surgical Procedures | 6 | 2025 | 340 | 1.330 |
Why?
| | Prognosis | 35 | 2025 | 4293 | 1.270 |
Why?
| | Pancreas | 9 | 2025 | 342 | 1.180 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 17 | 2025 | 1958 | 1.170 |
Why?
| | Gastrectomy | 3 | 2025 | 161 | 1.160 |
Why?
| | Retrospective Studies | 65 | 2026 | 17101 | 1.100 |
Why?
| | Deoxycytidine | 9 | 2025 | 221 | 1.050 |
Why?
| | Celiac Artery | 5 | 2023 | 20 | 1.010 |
Why?
| | Aged | 54 | 2026 | 25947 | 0.950 |
Why?
| | Japan | 9 | 2025 | 143 | 0.950 |
Why?
| | Adenocarcinoma | 8 | 2026 | 931 | 0.930 |
Why?
| | Biliary Tract Surgical Procedures | 2 | 2025 | 28 | 0.920 |
Why?
| | Robotics | 2 | 2023 | 87 | 0.900 |
Why?
| | CA-19-9 Antigen | 6 | 2025 | 34 | 0.890 |
Why?
| | Postoperative Complications | 18 | 2026 | 2920 | 0.870 |
Why?
| | Pancreatic Fistula | 7 | 2025 | 35 | 0.860 |
Why?
| | Carcinoma, Hepatocellular | 3 | 2021 | 372 | 0.840 |
Why?
| | Humans | 119 | 2026 | 144957 | 0.830 |
Why?
| | Stomach Neoplasms | 1 | 2025 | 128 | 0.820 |
Why?
| | Gastroenterology | 2 | 2023 | 189 | 0.820 |
Why?
| | Gastric Stump | 1 | 2023 | 1 | 0.810 |
Why?
| | Chemotherapy, Adjuvant | 10 | 2026 | 421 | 0.780 |
Why?
| | Middle Aged | 50 | 2026 | 35928 | 0.770 |
Why?
| | Adenoma | 2 | 2025 | 218 | 0.720 |
Why?
| | Tegafur | 3 | 2025 | 12 | 0.690 |
Why?
| | Oxonic Acid | 3 | 2025 | 13 | 0.690 |
Why?
| | Survival Rate | 14 | 2026 | 2092 | 0.690 |
Why?
| | Nomograms | 1 | 2022 | 59 | 0.680 |
Why?
| | Neoplasm Staging | 8 | 2025 | 1465 | 0.670 |
Why?
| | Biomarkers, Tumor | 8 | 2025 | 1322 | 0.660 |
Why?
| | Neoplasm Recurrence, Local | 7 | 2026 | 1141 | 0.650 |
Why?
| | Klatskin Tumor | 3 | 2025 | 18 | 0.650 |
Why?
| | Aged, 80 and over | 18 | 2026 | 8279 | 0.640 |
Why?
| | Cystadenoma, Serous | 1 | 2020 | 18 | 0.630 |
Why?
| | Neuroendocrine Tumors | 2 | 2023 | 114 | 0.630 |
Why?
| | Treatment Outcome | 26 | 2025 | 11695 | 0.630 |
Why?
| | Vascular Neoplasms | 1 | 2020 | 18 | 0.620 |
Why?
| | Internationality | 1 | 2020 | 156 | 0.610 |
Why?
| | Cystadenocarcinoma, Serous | 1 | 2020 | 84 | 0.590 |
Why?
| | Female | 56 | 2026 | 78376 | 0.580 |
Why?
| | Practice Patterns, Physicians' | 3 | 2025 | 1358 | 0.570 |
Why?
| | Duodenal Neoplasms | 3 | 2023 | 26 | 0.560 |
Why?
| | Male | 53 | 2026 | 72406 | 0.560 |
Why?
| | Angiography | 1 | 2018 | 208 | 0.540 |
Why?
| | Adult | 34 | 2026 | 40506 | 0.520 |
Why?
| | Neoplasm Invasiveness | 6 | 2025 | 509 | 0.510 |
Why?
| | Patient Compliance | 1 | 2021 | 589 | 0.510 |
Why?
| | Multidetector Computed Tomography | 1 | 2017 | 40 | 0.510 |
Why?
| | Thrombosis | 2 | 2024 | 393 | 0.470 |
Why?
| | Biliary Tract Neoplasms | 2 | 2025 | 31 | 0.450 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 384 | 0.450 |
Why?
| | Coronavirus Infections | 1 | 2020 | 378 | 0.440 |
Why?
| | Fibrin Tissue Adhesive | 2 | 2025 | 20 | 0.440 |
Why?
| | Polyglycolic Acid | 2 | 2025 | 44 | 0.440 |
Why?
| | Surgical Mesh | 2 | 2025 | 50 | 0.430 |
Why?
| | Operative Time | 5 | 2026 | 175 | 0.420 |
Why?
| | Common Bile Duct Neoplasms | 2 | 2025 | 27 | 0.410 |
Why?
| | DNA Damage | 1 | 2017 | 430 | 0.410 |
Why?
| | Ultrasonography | 1 | 2018 | 770 | 0.410 |
Why?
| | Drainage | 3 | 2025 | 185 | 0.410 |
Why?
| | Ampulla of Vater | 2 | 2025 | 39 | 0.410 |
Why?
| | Dissection | 5 | 2024 | 56 | 0.400 |
Why?
| | Proportional Hazards Models | 5 | 2026 | 1325 | 0.400 |
Why?
| | Antineoplastic Agents | 2 | 2021 | 2197 | 0.380 |
Why?
| | Neoplasms, Multiple Primary | 2 | 2025 | 58 | 0.370 |
Why?
| | Precision Medicine | 1 | 2016 | 458 | 0.350 |
Why?
| | Fluorouracil | 7 | 2025 | 235 | 0.340 |
Why?
| | Embolization, Therapeutic | 2 | 2024 | 242 | 0.340 |
Why?
| | Diabetes Mellitus | 3 | 2025 | 1098 | 0.340 |
Why?
| | Blood Loss, Surgical | 3 | 2026 | 112 | 0.330 |
Why?
| | Jejunum | 3 | 2024 | 35 | 0.320 |
Why?
| | Paclitaxel | 7 | 2025 | 256 | 0.310 |
Why?
| | Leucovorin | 6 | 2025 | 101 | 0.310 |
Why?
| | Cholangiocarcinoma | 2 | 2023 | 106 | 0.300 |
Why?
| | Diarrhea | 3 | 2026 | 192 | 0.290 |
Why?
| | Minimally Invasive Surgical Procedures | 3 | 2025 | 192 | 0.290 |
Why?
| | Transcription Factors | 1 | 2017 | 1742 | 0.280 |
Why?
| | Follow-Up Studies | 10 | 2025 | 5417 | 0.280 |
Why?
| | Sweden | 2 | 2025 | 111 | 0.270 |
Why?
| | Disease-Free Survival | 3 | 2025 | 769 | 0.270 |
Why?
| | Hepatic Veins | 2 | 2024 | 32 | 0.260 |
Why?
| | Splenic Artery | 2 | 2024 | 13 | 0.260 |
Why?
| | Magnetic Resonance Imaging | 2 | 2025 | 3869 | 0.250 |
Why?
| | Incisional Hernia | 1 | 2026 | 3 | 0.240 |
Why?
| | Abdominal Wound Closure Techniques | 1 | 2026 | 8 | 0.240 |
Why?
| | Fasciotomy | 1 | 2026 | 23 | 0.240 |
Why?
| | Collateral Circulation | 1 | 2025 | 19 | 0.240 |
Why?
| | Albumins | 5 | 2025 | 118 | 0.230 |
Why?
| | Hemostasis, Surgical | 1 | 2025 | 27 | 0.230 |
Why?
| | Peritoneal Lavage | 1 | 2025 | 8 | 0.230 |
Why?
| | Clinical Decision-Making | 2 | 2020 | 359 | 0.230 |
Why?
| | Leiomyosarcoma | 1 | 2025 | 28 | 0.230 |
Why?
| | Renal Veins | 1 | 2025 | 18 | 0.230 |
Why?
| | Surgical Stapling | 1 | 2025 | 16 | 0.230 |
Why?
| | Anatomic Landmarks | 1 | 2025 | 31 | 0.230 |
Why?
| | Abdominal Neoplasms | 1 | 2025 | 47 | 0.230 |
Why?
| | Pericardium | 1 | 2025 | 62 | 0.220 |
Why?
| | Splenomegaly | 1 | 2024 | 14 | 0.220 |
Why?
| | Vena Cava, Inferior | 1 | 2025 | 81 | 0.220 |
Why?
| | Surgery, Computer-Assisted | 1 | 2025 | 84 | 0.220 |
Why?
| | Caveolin 1 | 1 | 2024 | 20 | 0.220 |
Why?
| | Induction Chemotherapy | 1 | 2024 | 87 | 0.210 |
Why?
| | Chemoradiotherapy | 2 | 2025 | 239 | 0.210 |
Why?
| | Adenocarcinoma, Mucinous | 2 | 2022 | 76 | 0.210 |
Why?
| | Liver Failure | 1 | 2024 | 83 | 0.210 |
Why?
| | Age Factors | 2 | 2022 | 3335 | 0.210 |
Why?
| | Metastasectomy | 1 | 2024 | 19 | 0.200 |
Why?
| | Succinimides | 1 | 2023 | 21 | 0.200 |
Why?
| | Drug Combinations | 3 | 2025 | 392 | 0.190 |
Why?
| | Gadolinium DTPA | 2 | 2025 | 68 | 0.190 |
Why?
| | Cohort Studies | 4 | 2024 | 5965 | 0.190 |
Why?
| | Nutritional Status | 1 | 2025 | 354 | 0.190 |
Why?
| | Pancreaticojejunostomy | 1 | 2022 | 9 | 0.190 |
Why?
| | Preoperative Care | 1 | 2025 | 380 | 0.190 |
Why?
| | Adenocarcinoma, Papillary | 1 | 2022 | 11 | 0.180 |
Why?
| | Cholestasis | 2 | 2022 | 219 | 0.180 |
Why?
| | Feasibility Studies | 5 | 2025 | 1095 | 0.180 |
Why?
| | Anastomosis, Surgical | 4 | 2023 | 157 | 0.180 |
Why?
| | Hemangiosarcoma | 1 | 2022 | 23 | 0.180 |
Why?
| | Imaging, Three-Dimensional | 1 | 2025 | 583 | 0.180 |
Why?
| | Postoperative Hemorrhage | 1 | 2023 | 104 | 0.180 |
Why?
| | Carcinoma | 1 | 2023 | 228 | 0.170 |
Why?
| | Spleen | 1 | 2023 | 508 | 0.170 |
Why?
| | Antigens, Tumor-Associated, Carbohydrate | 1 | 2020 | 8 | 0.170 |
Why?
| | Tumor Burden | 1 | 2022 | 322 | 0.160 |
Why?
| | Surgeons | 1 | 2025 | 340 | 0.160 |
Why?
| | Portal System | 1 | 2020 | 12 | 0.160 |
Why?
| | Stents | 2 | 2022 | 556 | 0.160 |
Why?
| | Ischemia | 1 | 2023 | 421 | 0.160 |
Why?
| | Predictive Value of Tests | 3 | 2025 | 2118 | 0.150 |
Why?
| | Hepatic Artery | 1 | 2020 | 53 | 0.150 |
Why?
| | Contrast Media | 2 | 2025 | 488 | 0.150 |
Why?
| | Benchmarking | 1 | 2020 | 188 | 0.150 |
Why?
| | Orotate Phosphoribosyltransferase | 1 | 2018 | 3 | 0.140 |
Why?
| | Indocyanine Green | 1 | 2018 | 42 | 0.140 |
Why?
| | Biology | 3 | 2024 | 91 | 0.140 |
Why?
| | Lymph Nodes | 2 | 2023 | 502 | 0.140 |
Why?
| | Fluorescence | 1 | 2018 | 161 | 0.140 |
Why?
| | Consensus | 1 | 2020 | 489 | 0.140 |
Why?
| | Multivariate Analysis | 2 | 2023 | 1540 | 0.140 |
Why?
| | Intraoperative Care | 1 | 2018 | 62 | 0.130 |
Why?
| | Betacoronavirus | 1 | 2020 | 286 | 0.130 |
Why?
| | Lymph Node Excision | 3 | 2024 | 173 | 0.130 |
Why?
| | Comorbidity | 1 | 2022 | 1660 | 0.120 |
Why?
| | Patient Safety | 1 | 2020 | 349 | 0.120 |
Why?
| | Practice Guidelines as Topic | 1 | 2024 | 1563 | 0.120 |
Why?
| | Fluorocarbons | 1 | 2018 | 143 | 0.120 |
Why?
| | Hospitals, University | 1 | 2016 | 176 | 0.120 |
Why?
| | Immunohistochemistry | 2 | 2018 | 1718 | 0.120 |
Why?
| | Biopsy, Needle | 1 | 2016 | 183 | 0.120 |
Why?
| | Sex Factors | 1 | 2022 | 2114 | 0.120 |
Why?
| | Hypoglycemic Agents | 1 | 2025 | 1389 | 0.110 |
Why?
| | Statistics, Nonparametric | 1 | 2016 | 427 | 0.110 |
Why?
| | Incidence | 3 | 2026 | 2883 | 0.110 |
Why?
| | Cell Survival | 1 | 2018 | 1098 | 0.110 |
Why?
| | Risk Factors | 4 | 2026 | 10792 | 0.110 |
Why?
| | DNA Repair | 1 | 2017 | 256 | 0.110 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2020 | 1462 | 0.110 |
Why?
| | Insulin | 1 | 2025 | 2507 | 0.100 |
Why?
| | Liver | 1 | 2023 | 1888 | 0.100 |
Why?
| | Ligation | 2 | 2024 | 92 | 0.100 |
Why?
| | Ultraviolet Rays | 1 | 2017 | 388 | 0.100 |
Why?
| | Reactive Oxygen Species | 1 | 2017 | 621 | 0.100 |
Why?
| | Prospective Studies | 3 | 2025 | 7997 | 0.100 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 966 | 0.100 |
Why?
| | Health Care Surveys | 2 | 2025 | 539 | 0.100 |
Why?
| | Carcinoembryonic Antigen | 2 | 2023 | 39 | 0.100 |
Why?
| | Young Adult | 2 | 2022 | 14126 | 0.090 |
Why?
| | Breast Neoplasms | 1 | 2025 | 2456 | 0.090 |
Why?
| | Thyrotropin | 2 | 2024 | 118 | 0.090 |
Why?
| | Splenectomy | 2 | 2023 | 65 | 0.090 |
Why?
| | Time Factors | 4 | 2026 | 7183 | 0.090 |
Why?
| | Patient Selection | 1 | 2016 | 719 | 0.090 |
Why?
| | Computational Biology | 1 | 2017 | 681 | 0.090 |
Why?
| | Surveys and Questionnaires | 2 | 2025 | 6053 | 0.090 |
Why?
| | Pandemics | 1 | 2020 | 1695 | 0.090 |
Why?
| | Mutation | 2 | 2023 | 4099 | 0.080 |
Why?
| | Lung Neoplasms | 1 | 2023 | 2642 | 0.080 |
Why?
| | Reproducibility of Results | 1 | 2018 | 3415 | 0.080 |
Why?
| | Cell Line, Tumor | 1 | 2017 | 3550 | 0.070 |
Why?
| | Apoptosis | 1 | 2017 | 2430 | 0.070 |
Why?
| | Hospital Mortality | 2 | 2024 | 1031 | 0.070 |
Why?
| | Length of Stay | 2 | 2025 | 1337 | 0.060 |
Why?
| | Polydioxanone | 1 | 2026 | 5 | 0.060 |
Why?
| | Risk Assessment | 1 | 2016 | 3676 | 0.060 |
Why?
| | Organoplatinum Compounds | 1 | 2025 | 66 | 0.060 |
Why?
| | Cytodiagnosis | 1 | 2025 | 31 | 0.060 |
Why?
| | Margins of Excision | 1 | 2025 | 51 | 0.060 |
Why?
| | Suture Techniques | 1 | 2026 | 131 | 0.060 |
Why?
| | Preoperative Period | 1 | 2025 | 149 | 0.050 |
Why?
| | Tissue Adhesives | 1 | 2024 | 22 | 0.050 |
Why?
| | Tomography, X-Ray Computed | 2 | 2025 | 2738 | 0.050 |
Why?
| | Pancreatitis | 1 | 2025 | 145 | 0.050 |
Why?
| | Neoplasm, Residual | 1 | 2025 | 139 | 0.050 |
Why?
| | Pneumonectomy | 1 | 2026 | 169 | 0.050 |
Why?
| | United States | 1 | 2021 | 15988 | 0.050 |
Why?
| | Smad4 Protein | 1 | 2023 | 34 | 0.050 |
Why?
| | Hepatic Duct, Common | 1 | 2023 | 5 | 0.050 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2023 | 73 | 0.050 |
Why?
| | Cattle | 1 | 2025 | 1000 | 0.050 |
Why?
| | Multicenter Studies as Topic | 1 | 2024 | 405 | 0.050 |
Why?
| | Propensity Score | 1 | 2025 | 367 | 0.050 |
Why?
| | Bile Ducts, Intrahepatic | 1 | 2023 | 63 | 0.050 |
Why?
| | Reoperation | 1 | 2025 | 631 | 0.050 |
Why?
| | Postoperative Care | 1 | 2024 | 288 | 0.050 |
Why?
| | Abdomen | 1 | 2023 | 141 | 0.050 |
Why?
| | Adolescent | 1 | 2022 | 22453 | 0.040 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2023 | 253 | 0.040 |
Why?
| | Neoplasm Metastasis | 1 | 2024 | 695 | 0.040 |
Why?
| | Combined Modality Therapy | 1 | 2024 | 1268 | 0.040 |
Why?
| | Lymphatic Metastasis | 1 | 2022 | 334 | 0.040 |
Why?
| | Survival Analysis | 1 | 2024 | 1385 | 0.040 |
Why?
| | Stomach | 1 | 2021 | 109 | 0.040 |
Why?
| | Plastics | 1 | 2021 | 47 | 0.040 |
Why?
| | Intention to Treat Analysis | 1 | 2020 | 80 | 0.040 |
Why?
| | Reproduction | 1 | 2022 | 207 | 0.040 |
Why?
| | Europe | 1 | 2021 | 412 | 0.040 |
Why?
| | Morbidity | 1 | 2021 | 323 | 0.040 |
Why?
| | Antigens, Neoplasm | 1 | 2022 | 272 | 0.040 |
Why?
| | Colectomy | 1 | 2020 | 107 | 0.040 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2023 | 531 | 0.040 |
Why?
| | Safety | 1 | 2021 | 356 | 0.040 |
Why?
| | Equilibrative Nucleoside Transporter 1 | 1 | 2018 | 20 | 0.040 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2024 | 1721 | 0.030 |
Why?
| | Recurrence | 1 | 2021 | 1135 | 0.030 |
Why?
| | Colonic Neoplasms | 1 | 2020 | 260 | 0.030 |
Why?
| | Disease Progression | 1 | 2023 | 2852 | 0.030 |
Why?
| | Blood Glucose | 1 | 2025 | 2330 | 0.030 |
Why?
| | Palliative Care | 1 | 2022 | 1008 | 0.020 |
Why?
| | Gene Expression | 1 | 2018 | 1490 | 0.020 |
Why?
| | Lung | 1 | 2023 | 4109 | 0.020 |
Why?
| | Analgesics, Opioid | 1 | 2018 | 1143 | 0.020 |
Why?
| | Animals | 1 | 2025 | 38109 | 0.010 |
Why?
|
|
Oba's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|